The application of PD-L1 inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer
PD-L1抑制剂联合化疗在广泛期小细胞肺癌患者中的应用

摘要

目的 研究程序性死亡受体配体1（PD-L1）抑制剂联合化疗在广泛期小细胞肺癌患者中的应用价值。方法 选择院内2023年3月至2024年10月期间收治的60例广泛期小细胞肺癌患者，随机数字表法分为研究组、对照组，各30例。对照组接受常规化疗，研究组同时给予PD-L1抑制剂干预，开展6个周期治疗。对比两组患者疗效、生存情况与不良反应发生情况。结果 研究组客观缓解率（ORR）高于对照组，研究组中位无进展生存期（PFS）、中位总生存期（OS）高于对照组，不良反应发生率低于对照组，差异有统计学意义（P＜0.05）。结论 对广泛期小细胞肺癌患者开展PD-L1抑制剂联合化疗干预，能够提升疗效，延长患者生存期，同时降低不良反应风险。

Abstract

Objective To investigate the application value of programmed death ligand 1 (PD-L1) inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer.
Methods Sixty patients with extensive-stage small cell lung cancer admitted to the hospital from March 2023 to October 2024 were selected and divided into a study group and a control group by random number table method, with 30 cases in each group. The control group received conventional chemotherapy, while the study group was simultaneously intervened with PD-L1 inhibitors for 6 cycles of treatment. The therapeutic effects, survival conditions and occurrence of adverse reactions of the two groups of patients were compared.
Results The objective response rate (ORR) of the study group was higher than that of the control group. The median progression-free survival (PFS) and median overall survival (OS) of the study group were higher than those of the control group, and the incidence of adverse reactions was lower than that of the control group. The differences were statistically significant (P < 0.05).
Conclusion   The intervention of PD-L1 inhibitors combined with chemotherapy for patients with extensive-stage small cell lung cancer can improve the therapeutic effect, prolong the survival period of patients, and reduce the risk of adverse reactions at the same time.